Together with established favourable-risk WNT medulloblastomas in patients younger than 16 years (20 [15%] of 136 patients; appendix pp 5–6) and TP53wild-type SHH medulloblastomas (11 [8%] of 136 tumours; appendix pp 7–8), these newly identified chromosomal signatures identified 69 (51%) of 134 (two SHH tumours had unknown TP53 status and were therefore excluded from the calculation) molecularly characterised patients with medulloblastoma from the HIT-SIOP PNET 4 cohort with a favourable prognosis (5-year event-free survival of 100%). This evidence concerns the gene TP53 and medulloblastoma.